Leerink Partnrs Issues Negative Forecast for COGT Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Equities researchers at Leerink Partnrs lowered their Q4 2025 EPS estimates for Cogent Biosciences in a research note issued to investors on Monday, July 7th. Leerink Partnrs analyst A. Berens now forecasts that the technology company will earn ($0.58) per share for the quarter, down from their prior estimate of ($0.57). The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Cogent Biosciences' FY2026 earnings at ($1.59) EPS and FY2027 earnings at $1.04 EPS.

Several other brokerages have also weighed in on COGT. Robert W. Baird raised their price objective on shares of Cogent Biosciences from $7.00 to $9.00 and gave the company a "neutral" rating in a research report on Tuesday, July 8th. Needham & Company LLC restated a "hold" rating on shares of Cogent Biosciences in a report on Tuesday, June 17th. HC Wainwright upped their price objective on shares of Cogent Biosciences from $12.00 to $22.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. Guggenheim reissued a "buy" rating and set a $17.00 target price on shares of Cogent Biosciences in a research report on Tuesday, July 8th. Finally, Leerink Partners boosted their price target on Cogent Biosciences from $16.00 to $18.00 and gave the stock an "outperform" rating in a research report on Monday, July 7th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $18.00.

Cogent Biosciences Stock Performance

Shares of Cogent Biosciences stock traded up $0.13 during trading on Thursday, hitting $10.98. 3,386,326 shares of the stock traded hands, compared to its average volume of 1,574,713. The stock has a market cap of $1.25 billion, a P/E ratio of -5.97 and a beta of 1.88. The company has a fifty day moving average price of $6.54 and a two-hundred day moving average price of $6.82. Cogent Biosciences has a twelve month low of $3.72 and a twelve month high of $12.61.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last issued its earnings results on Tuesday, May 6th. The technology company reported ($0.52) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.04.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Strs Ohio acquired a new stake in shares of Cogent Biosciences in the first quarter valued at about $36,000. CWM LLC grew its holdings in Cogent Biosciences by 11,869.9% in the 1st quarter. CWM LLC now owns 8,738 shares of the technology company's stock valued at $52,000 after buying an additional 8,665 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in Cogent Biosciences in the 4th quarter valued at approximately $78,000. Hsbc Holdings PLC bought a new position in Cogent Biosciences in the 4th quarter worth approximately $81,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Cogent Biosciences during the fourth quarter worth approximately $88,000.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.